Journal of General Internal Medicine

, Volume 14, Issue 10, pp 625–632

Benefits and risks of third-generation oral contraceptives

  • Erin S. LeBlanc
  • Ami Laws
Clinical Reviews


OBJECTIVE: To evaluate the risks and benefits of third-generation oral contraceptives.

DATA SOURCES: A medline search was done for English language articles published from 1985 through 1998 relating to the side-effect profile of third-generation oral contraceptives or their association with cardiovascular or thromboembolic disease. All articles containing original data were included.

DATA SYNTHESIS: The risk of venous thromboembolism appears to be 1.5- to 2.7-fold greater in users of third-generation, compared with second-generation, oral contraceptives. Compared with nonusers, women who use third-generation oral contraceptives may have a 4.8- to 9.4-fold greater risk of venous thromboembolism. Users of third-generation oral contraceptives do not appear to have an increased risk of myocardial infarction compared with nonusers and may have risk of myocardial infarction of 0.26 to 0.7 compared with second-generation users. Whether third-generation oral contraceptives are associated with a decreased stroke risk is still not clear.

CONCLUSIONS: Although third-generation oral contraceptives most likely increase a user’s risk of venous thromboembolism, their improved side-effect profile and their possible decreased association with myocardial infarction and stroke may make them a useful new class of oral contraceptives for most women except those at increased risk of venous thrombosis.

Key words

contraceptives, oral desogestrel thromboembolism myocardial infarction cerebrovascular disorders 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Stampfer MJ, Willet WC, Colditz GA, Speizer FE, Hennekens CH. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med. 1988;319:1313–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Lewis M, Heinemann A, Spitzer W, MacRae K, Bruppacher R, for the Transnational Research Group on Oral Contraceptives and the Health of Young Women. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Contraception. 1997;56:129–40.PubMedCrossRefGoogle Scholar
  3. 3.
    Petiti D, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel H. Stroke in users of low-dose oral contraceptives. N Engl J Med. 1996;335:8–15.CrossRefGoogle Scholar
  4. 4.
    Schwartz S, Siscovick D, Longstreth WT Jr, Psay B, Beverly K. Use of low-dose oral contraceptives and stoke in young women. Ann Intern Med. 1997;127:596–603.PubMedGoogle Scholar
  5. 5.
    Runnebaum B, Grunwald K, Rabe T. The efficacy and tolerability of norgestimate/ethinyl estradiol (250 µg of norgestimate/35 µg of ethinyl estradiol): results of an open, multicenter study of 59,701 women. Am J Obstet. 1992;166:1963–8.Google Scholar
  6. 6.
    Palatsi R, Hirvensalo E, Liukko P, et al. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives. Acta Derm Venereol (Stockh). 1984;64:517–23.Google Scholar
  7. 7.
    Bilotta P, Favilli S. Clinical evaluation of a monophasic ethinyl estradiol/desogestrel-containing oral contraceptive. Arzneim-Forsch Drug Res. 1988;36:932–4.Google Scholar
  8. 8.
    Corson SL. Efficacy and clinical profile of a new oral contraceptive containing norgestimate. Acta Obstet Gynecol Scand. 1990;152(suppl):25–31.Google Scholar
  9. 9.
    Huber J. Clinical experience with a new norgestimate-containing oral contraceptive. Int J Fertil. 1991;36(suppl):25–31.PubMedGoogle Scholar
  10. 10.
    Chapdelaine A, Desmarais J, Derman RJ. Clinical evidence of the minimal androgenic activity of norgestimate. Int J Fertil. 1989;34:347–52.PubMedGoogle Scholar
  11. 11.
    Cullberg G, Samsioe G, Andersen RF, et al. Two oral contraceptives, efficacy, serum proteins, and lipid metabolism: a comparative multicentre study on a triphasic and a fixed dose combination. Contraception. 1982;26:229–43.PubMedCrossRefGoogle Scholar
  12. 12.
    Walling M. A multicenter efficacy and safety study of an oral contraceptive containing 150 µg desogestrel and 30 µg ethinyl estradiol. Contraception. 1992;46:313–26.PubMedCrossRefGoogle Scholar
  13. 13.
    Andolsek KM. Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agent. Acta Obstet Gynecol Scand. 1992;71:22–6.Google Scholar
  14. 14.
    Hoppe G. Gestodene, an innovative progestogen. Contraception. 1988;37:493–501.PubMedCrossRefGoogle Scholar
  15. 15.
    Speroff L, DeCherney A, and The Advisory Board for the New Progestins. Evaluation of a new generation of oral contraceptives. Obstet Gynecol. 1993;81:1034–47.PubMedGoogle Scholar
  16. 16.
    World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and oral contraceptives: results of international multicentre case-control study. Lancet. 1995;346:1575–82.CrossRefGoogle Scholar
  17. 17.
    World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet. 1995;346:1582–88.CrossRefGoogle Scholar
  18. 18.
    Spitzer WO, Lewis AL, Heinemann LAJ, Thorogood M, MacRae KD, on behalf of the Transnational Research Group on Oral Contraceptives and the Health of Young Women. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ. 1996;312:83–8.PubMedGoogle Scholar
  19. 19.
    Bloemenkamp K, Rosendaal FR, Helmerhorst FM, Buller H, Vandenbroucke J. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet. 1995;346:1593–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a case control study. Contraception. 1998;57:291–301.PubMedCrossRefGoogle Scholar
  21. 21.
    Bloemenkamp K, Rosendaal F, Buller H, Helmerhorst F, Colly LP, Vandenbroucke J. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med. 1999;159:65–70.PubMedCrossRefGoogle Scholar
  22. 22.
    Jick H, Jick S, Gurewich V, Myers M, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995;346:1589–93.PubMedCrossRefGoogle Scholar
  23. 23.
    Farmer R, Lawrenson R, Thompson C, Kennedy J, Hambleton I. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet. 1997;349:83–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Lewis M, Heinemann LA, MacRae K, Bruppacher R, Spitzer W, with the Transnational Research Group on Oral Contraceptives and the Health of Young Women. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception. 1996;54:5–13.PubMedCrossRefGoogle Scholar
  25. 25.
    Lauritzen C. Comments on Desogestrel and Gestodene (third generation progestogens) and the incidence of thromboembolism. Horm Metab Res. 1996;28:225–47.Google Scholar
  26. 26.
    Jick H, Jick SS, Myers MW, Vasilakis C. Third-generation oral contraceptives and venous thrombosis. Lancet. 1997;349:731–2.PubMedCrossRefGoogle Scholar
  27. 27.
    Poulter NR, Change CL, Marmot M, Farley TMM, Meirik O. Third-generation oral contraceptives and venous thrombosis. Lancet. 1997;349:732.PubMedCrossRefGoogle Scholar
  28. 28.
    Lidegaard O. The influence of thrombotic risk factors when oral contraceptives are prescribed. Acta Obstet Gynecol Scand. 1997;76:252–60.PubMedGoogle Scholar
  29. 29.
    Jamin C, de Mouzon J. Selective prescribing of third generation oral contraceptives. Contraception. 1996;54:55–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Dahlback, B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood. 1995;85:607–14.PubMedGoogle Scholar
  31. 31.
    Vandenbrouke JP, Koster T, Briet E, Reitsma PH, Brtina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453–7.CrossRefGoogle Scholar
  32. 32.
    Helmerhorst F, Bloemenkamp K, Rosendaal F, Vandenbrouke J. Oral contraceptives and thrombotic disease: risk of venous thromboembolism. Thromb Haemost. 1997;78:327–33.PubMedGoogle Scholar
  33. 33.
    Farley TM, Meirik O, Poulter NR, Chang CL, Marmot MG. Oral contraceptives and thrombotic diseases: impact of new epidemiological studies. Contraception. 1996;54:193–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Rosing J, Tans G, Nicolaes GAF, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol. 1997;97:233–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Darney PD. OC practice guidelines: minimizing side effects. Int J Fertil. 1997;42(suppl 1):158–69.Google Scholar
  36. 36.
    Lindstedt G, Lundberg PA, Lapidis L, et al. Low sex-hormonebinding globulin concentration as an independent risk factor for the development of non-insulin dependent diabetes: twelve-year follow up of population study of women in Gothenburg. Sweden. Diabetes. 1991;40:123–8.Google Scholar
  37. 37.
    Rosa JC. The varying effects of progestins on lipid levels and cardiovascular disease. Am J Obstet Gynecol. 1988;158:1621–9.PubMedGoogle Scholar
  38. 38.
    Kakis G, Powell M, Marshall A, et al. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids. Int J Fertil Menopausal Stud. 1994;39:283–91.PubMedGoogle Scholar
  39. 39.
    Krauss RM, Burkman RT. The metabolic impact of oral contraceptives. Am J Obstet Gynecol. 1992;167:1177–84.PubMedGoogle Scholar
  40. 40.
    Greenlund KJ, Webber LS, Srinivasan S, et al. Associations of oral contraceptive use with serum lipids and lipoproteins in young women: the Bogalusa heart study. Ann Epidemiol. 1997;7:561–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Notelovitz M, Feldman EB, Gillespy M, Gudat J. Lipid and lipoprotein changes in women taking low-dose, triphasic oral contraceptives: a controlled, comparative, 12-month clinical trial. Am J Obstet Gynecol. 1989;160:1269–80.PubMedGoogle Scholar
  42. 42.
    London RS, Chapdelaine A, Upmalis D, Olson W, Smith J. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive. Acta Obstet Gynecol Scand. 1992;71:9–14.CrossRefGoogle Scholar
  43. 43.
    Becker H. Supportive European data on a new oral contraceptive containing norgestimate. Acta Obstet Gynecol Scand. 1990;152(suppl):33–9.Google Scholar
  44. 44.
    Mann JI, Inman WH. Oral contraceptives and death from myocardial infarction. BMJ. 1975;2:245–8.PubMedGoogle Scholar
  45. 45.
    Mann JI, Inman WH, Thorogood M. Oral contraceptive use in older women and fatal myocardial infarction. BMJ. 1976;2:445–7.PubMedGoogle Scholar
  46. 46.
    Rosenberg L, Hennekens CH, Rosner B. Oral contraceptive use in relation to nonfatal myocardial infarction. Am J Epidemiol. 1980;111:59–66.PubMedGoogle Scholar
  47. 47.
    Shapiro S, Slone D, Rosenberg L, et al. Oral-contraceptive use in relation to myocardial infarction. Lancet. 1979;1:743–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Ory HW. Association between oral contraceptives and myocardial infarction. JAMA. 1977;237:2619–22.PubMedCrossRefGoogle Scholar
  49. 49.
    Slone D, Shapiro S, Kaufman D, et al. Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N Engl J Med. 1981;305:420–4.PubMedCrossRefGoogle Scholar
  50. 50.
    Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners’ oral contraception study. BMJ. 1989;298:165–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Rosenberg L, Kaufman DW, Helmrich SP. Myocardial infarction and cigarette smoking in women younger than 50 years of age. JAMA. 1985;253:2965–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Rosenberg L, Palmer JR, Lesko SM, Shapiro S. Oral contraceptive use and the risk of myocardial infarction. Am J Epidemiol. 1990;131:1009–16.PubMedGoogle Scholar
  53. 53.
    Thorogood M, Mann J, Murphy M, Vessey M. Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case-control study. Br J Obstet Gynaecol. 1991;98:1245–53.PubMedGoogle Scholar
  54. 54.
    Sidney S, Petitti DB, Quesenberry CP, Klatsky AR, Ziel HK, Wolf S. Myocardial infarction in users of low-dose oral contraceptives. Obstet Gynaecol. 1996;88:939–44.CrossRefGoogle Scholar
  55. 55.
    Sidney S, Siscovick DS, Petitti DB, et al. Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies. Circulation. 1998;98:1058–63.PubMedGoogle Scholar
  56. 56.
    WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone contraception. Acute myocardial infarction and combined oral contraceptives. Results of and international multicentre case-control study. Lancet. 1997;349:1202–9.CrossRefGoogle Scholar
  57. 57.
    Jick H, Jick S, Myers M, Vasilakis C. Risk of acute myocardial infarction and low-dose combined oral contraceptives. Lancet. 1996;347:627–8.PubMedCrossRefGoogle Scholar
  58. 58.
    WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ishaemic stroke and combined oral contraceptives. Results of an international, multicentre, case-control study. Lancet. 1996;348:498–505.CrossRefGoogle Scholar
  59. 59.
    Heinemann LA, Lewis MA, Thorogood M, et al., and the Transnational Research Group on Oral Contraceptives and the Health of Young Women. Case-control study of oral contraceptives and risk of thromboembolic stroke: results from international study on oral contraceptives and health of young women. BMJ. 1997;315:1502–4.PubMedGoogle Scholar
  60. 60.
    WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Hemorrhagic stroke, overall stroke risk, and combined oral contraceptives. Results of an international, multicentre, case-control study. Lancet. 1996;348:505–10.CrossRefGoogle Scholar
  61. 61.
    Heinemann LA, Lewis MA, Thorogood M, et al., and the Transnational Research Group on Oral Contraceptives and the Health of Young Women. Thromboembolic stroke in young women: a European case-control study on oral contraceptives. Contraception. 1998;57:29–37.PubMedCrossRefGoogle Scholar
  62. 62.
    Lewis MA, Sitzer WO, Heinemann LA, MacRae KD, Bruppacher R. Lowered risk of dying of heart attack with third generation pill may offset risk of dying of thromboembolism. BMJ. 1997;315:679–80.Google Scholar
  63. 63.
    Schwing PJ, Shelton J. Modeled estimates of myocardial infarction and venous thromboembolic disease in users of second and third generation oral contraceptives. Contraception. 1997;55:125–9.CrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 1999

Authors and Affiliations

  • Erin S. LeBlanc
    • 1
  • Ami Laws
    • 2
  1. 1.the Department of Internal MedicinePortland Veterans Affairs Medical CenterPortland
  2. 2.the Department of Internal MedicineStanford UniversityPalo Alto

Personalised recommendations